Attenuation of CKD Risk measured by Promarker^®D - the CANVAS Trial Results

Patients initiated on SGLT2 inhibitor therapy demonstrated reduced Promarker^®D scores as compared to placebo.

The prognostic ability of Promarker^®D to predict CKD was evaluated in the CANVAS (Canagliflozin Cardiovascular Assessment Study) — one of the largest clinical trials of SGLT2 Inhibitor therapy for type 2 diabetes to assess the test's ability to measure progression and attenuation of risk. A total of 2,008 participants were randomized to placebo or treatment arm (Canigliflozin) and evaluated for CKD risk over time using Promarker^®D.  The treatment arm cohort demonstrated significantly reduced test scores versus the placebo arm (p < 0.001).